With aging of populations, the worldwide population of persons with dementia will reach over 81 million by 2040, of which the most common cause is Alzheimer’s disease. Thus it is of great significance to have advances in early diagnosis and treatment of AD. Before that, it is important to have better understanding of its pathogenesis and method to diagnose it. It have been proved that magnetic resonance brain imaging, cerebrospinal fluid biomarkers, and Pittsburgh compound B and fluorodeoxyglucose positron emission tomography of the brain can facilitate an accurate diagnosis of Alzheimer’s disease in its early stage. For treatments, one area of clinical research is focused on treating the underlying disease pathology. Reduction of beta-amyloid
